No matter how hard we try, the truth is we can never really explore everything that is there to a human life. Some people certainly end up exploring more than others, but even they don’t get anywhere near the entire package. Nevertheless, this piece of reality hasn’t quite stopped us from attempting time and again to get there. All the generations that came before us formulated their own unique effort for the same, and when it was our turn, we found our answer in technology. It wouldn’t be wrong to say that by doing so we broke the mould. You see, even though every generation came up with something different, there was always some precedent that used to validate its core function. However, with technology, there seemed to be no such precedent. We had to walk an unfamiliar road, but soon the dividends would go on to fairly reward our courage, thus marking the beginning of a new era. Now, while technology was altering the whole spectrum, one area where it made the strongest impact turned out to be healthcare. The creation’s attributes slid swiftly alongside what the sector desperately needed at the time, and that pretty much became a reference point for the Medtech revolution. We haven’t stopped progressing ever since, and our latest step promises to guide us in expanding upon an under-the-radar subject.
PlateletBio, a company specializing inone-of-a-kind cell therapies, has officially announced that it willusher its new treatment for a rare bleeding disorder into the trial phase. The announcement comes on the back of a fresh investment worth $75.5 million from SymBiosis, K2 HealthVentures, and Oxford Finance. Despite all our achievements within the medical sector, we don’t have a single FDA-approved therapy in the market that treats immune thrombocytopenia, a blood disorder where an individual’s immune system misjudges their platelets to be foreign. Hence, PlateletBio’s therapy offers hope, and it does that for a lot of reasons. For instance, instead of introducing new DNA to the body by taking platelets from donors, PlateletBio manufactures them on their own with the help of growth and protein properties found in these platelets, a more effective approach which, for some reason, remains a bit untouched by the other companies.
This, of course, shouldn’t imply that no other organization is dabbling with translating blood components to cell therapies. The likes of Rubius Therapeutics have been reported to be working on similar treatments using red blood cells, but PlateletBio’s inventive take is rightfully dominating the moment.
“This is a major milestone for PlateletBio, adding capital and resources needed to advance our innovative platelet-like cell therapy science and manufacturing platform and support key corporate initiatives over the next 18 to 24 months,” Sam Rasty, the PlateletBio’s President and CEO.
